Migraine Briefs

Lasmiditan demonstrates superior pain freedom at 2 hours in at least 2 of 3 migraine attacks


 

Key clinical point: Lasmiditan is effective in the treatment of an acute migraine attack and demonstrates consistency of response across multiple migraine attacks

Major finding: Lasmiditan doses of 100 and 200 mg were superior to placebo for pain freedom at 2 hours during the first attack (odds ratio [OR], 3.8 and 4.6, respectively; P less than .001) and in at least 2 of 3 attacks (OR, 3.8 and 7.2, respectively; P less than .001). The incidence of severe adverse events was similar across treatment groups.

Study details: Findings are from CENTURION, a phase 3 study that randomly assigned patients with migraine with/without aura to either of 3 treatment groups for 4 attacks: lasmiditan 200 mg (n=536), lasmiditan 100 mg (n=539), or control (n=538).

Disclosures: The CENTURION study was sponsored by Eli Lilly and Company. Some authors including the lead author were full-time employees and minor stockholders at Eli Lilly and Company. Some authors reported receiving speaker fees and honorariums from different sources.

Source: Ashina M et al. Cephalalgia. 2021 Feb 4. doi: 10.1177/0333102421989232.

Recommended Reading

Reversion from chronic to episodic migraine with erenumab
Migraine ICYMI
Real-world effectiveness of erenumab in migraine
Migraine ICYMI
PFO closure reduces migraine: New meta-analysis
Migraine ICYMI
Researchers examine factors associated with opioid use among migraineurs
Migraine ICYMI
The true measure of cluster headache
Migraine ICYMI
Migraine: Triptan responders are more likely to respond to erenumab
Migraine ICYMI
Migraine linked to more than doubled risk for irritable bowel syndrome
Migraine ICYMI
Fewer headache days with erenumab in onabotulinumtoxin A resistant chronic migraine
Migraine ICYMI
Erenumab improves functional outcomes in patients with episodic migraine
Migraine ICYMI
Acute care of migraine and cluster headaches: Mainstay treatments and emerging strategies
Migraine ICYMI